Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
80938-69-8CCCCCCCCCC(=O)N[C@H](CN1CCOCC1)[C@H](O)c1ccccc1.ClHVJHJOYQTSEKPK-BLDCTAJRSA-N80938-69-8DTXSID401017468CHEMBL1255585Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
BeschreibungDL-threo PDMP is a mixture of ceramide analogs that contains two of the four possible stereoisomers of PDMP : D-threo-(1R,2R)-PDMP and L-threo-(1S,2S)-PDMP. DL-threo-PDMP inhibits glucosylceramide synthase by 33 and 48% in MDCK cell homogenates when used at concentrations of 5 and 10 μM. It reduces the synthesis of glucosylceramide, increases cellular ceramide, and induces cell cycle arrest in vitro. The ability to inhibit glucosylceramide synthase has been found to reside in the D-threo-(1R,2R) enantiomer. The D-threo-PDMP enantiomer is also responsible for inhibition of β-1,4-galactosyltransferase 6 and prevention of lactosylceramide synthesis, which is a promotor of neuroinflammation in mice during chronic experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. DL-threo-PDMP increases amyloid-β (1-42) (Aβ42) and Aβ39 production independent of ceramide metabolism via modulation of γ-secretase activity in HEK293 cells expressing the γ-secretase substrate SC100. [Matreya, LLC. Catalog No. 1719]
VerwendenDL-threo-PDMP can deplete cells and mice of their glucosphinolipids.
Wird geladen…
Wird geladen…
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…